U.S. Markets closed

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.41-3.20 (-10.45%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close30.61
Open29.54
Bid27.24 x 1100
Ask30.05 x 1000
Day's Range27.36 - 29.82
52 Week Range23.02 - 79.16
Volume211,369
Avg. Volume268,079
Market Cap899.667M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 18, 2021 - Aug 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.80
  • GlobeNewswire

    Nkarta to Participate at Upcoming Investor Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference: Cantor Virtual Global Healthcare ConferenceTuesday, September 28, 20214:00 p.m. ET - fireside chat presentation A simultaneous webcast of the presentation will be available on the Investors section of Nkarta’s website, www.nkartatx.c

  • GlobeNewswire

    Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

    Initial data from NKX101 clinical trial expected by end of 2021NKX019 patient dosing expected to start in 2H 2021Collaboration with CRISPR Therapeutics to develop gene-edited cell therapiesNew lease for commercial manufacturing center / headquarters to support rapid innovation and scaled production of NK cell therapies SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to

  • Benzinga

    Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site

    Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the research, development, and future commercial manufacturing of its cell therapy pipeline. The Company did not disclose the cost of the project. The facility will be a multi-product manufacturing site and is scheduled to come online by the end of 2023, Nkarta said. At full capacity, the facility should produce a commercial supply of mult